Targeting the ERK Signaling Pathway in Melanoma

Targeting the ERK Signaling Pathway in Melanoma

The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have opened a new era in the treatment of this tumor. Vemurafenib was the first specific kinase inhibitor approved for therapy of advanced melanomas harboring BRAF-activating mutations, followed by dabraf...

Full description

Bibliographic Details
Main Authors: Paola Savoia, Paolo Fava, Filippo Casoni, Ottavio Cremona
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:International Journal of Molecular Sciences
Subjects:
ERK pathway
target therapy
metastatic melanoma
BRAF inhibitors
MEK inhibitors
ERK inhibitors
NRAS inhibitors
melanoma treatment
Online Access:https://www.mdpi.com/1422-0067/20/6/1483

Similar Items

Similar Items